Pharmidex is a solution provider in
brain medicines research. Headquartered in London, we specialise in
predicting and assessing the ability of compounds to cross the
permeability barrier between
blood and brain –
the
Blood-Brain Barrier (BBB).
We are the only company in the world offering direct assessment of brain
penetrability –
NeuroPharmacoKinetics or NeuroPK for
short.
Working as a collaboration partner we add value to CNS drug discovery by
increasing the probability of success and reducing the time to market.
This is achieved through our innovative screens and patented
technologies and underpinned by our unique ability to integrate
neuroscience, DMPK and CNS drug discovery expertise.
|
|
What others
say about us |
